The article argues that AI will revolutionize drug discovery long before it can streamline clinical development, creating an abundance of candidate molecules but leaving patient trials as the main constraint. As discovery becomes commoditized and more assets target the same biology, real value will hinge on predictive toxicity, clinical efficacy, and strategic trial design.

The article shows U.S. office visits remain at about 70% of pre-pandemic levels, driving high vacancy rates and a flight to newer buildings. It also highlights research linking remote work—not AI—to rising youth unemployment, explores AI uptake among small employer firms versus solopreneurs, and details how emerging biotechs now lead in clinical trials and drug approvals.

Anthropic cut off access to its Mythos 5 and Fable 5 AI models to comply with new US export controls. Elon Musk became the world’s first trillionaire after SpaceX shares surged in its IPO. The update also covers a CRISPR method that targets “undruggable” cancers and the first working nuclear clocks from Chinese and European teams.

Today’s TLDR rundown covers SpaceX’s IPO oversubscribed by more than four times, OpenAI prepping steep token-price cuts ahead of an AI price war with Anthropic, and Stack Overflow’s new API-first knowledge platform for AI agents. Plus quick briefs on gene-therapy vision reversal and China’s first commercial brain implant.

10x Science built a platform that uses chemistry-based algorithms and AI agents to interpret complex mass spectrometry data, speeding up protein characterization for drug development. Backed by a $4.8 million seed round, it helps biotechs and pharma quickly validate AI-generated treatment candidates. The startup plans to refine its models and expand offerings by integrating broader cellular data.

AWS introduced Amazon Bio Discovery, an AI-driven platform that lets researchers run complex drug-design workflows without coding. It provides a library of biological foundation models, an AI agent for workflow setup and analysis, and links to lab partners for synthesis and testing, cutting months of work down to weeks.

Three MIT PhD students reverse-engineered Google's AlphaFold 3, creating Boltz-1 as an open-source alternative for drug discovery. Their platform enables pharmaceutical companies to conduct rapid and cost-effective drug-binding predictions while maintaining free access to the underlying models. Boltz aims to challenge commercial restrictions and offer a more accessible solution within the competitive landscape of AI in drug discovery.

Boltz is launching a transformative approach to drug design and biological research by combining AI and open science, enabling over 100,000 scientists to innovate faster. With a newly raised $28 million seed round and a partnership with Pfizer, Boltz aims to break down barriers in drug development through open-source models and accessible computational tools.